Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Predict Intell Med. 2019 Oct 10;11843:1–10. doi: 10.1007/978-3-030-32281-6_1

Table 1:

Summary of TADPOLE datasets D1–D4. Each subject has been allocated to either Cognitively Normal, MCI or AD group based on diagnosis at the rst available visit within each dataset.

Measure D1 D2 D3 D4
Subjects 1667 896 896 219
Cognitively Normal
Number (% total) 508 (30%) 369 (41%) 299 (33%) 94 (42%)
Visits per subject 8.3 ± 4.5 8.5 ± 4.9 1.0 ± 0.0 1.0 ± 0.2
Age 74.3 ± 5.8 73.6 ± 5.7 72.3 ± 6.2 78.4 ± 7.0
Gender (% male) 48% 47% 43% 47%
MMSE 29.1 ± 1.1 29.0 ± 1.2 28.9 ± 1.4 29.1 ± 1.1
Converters (% total CN) 18 (3.5%) 9 (2.4%) - -

Mild Cognitive Impairment
Number (% total) 841 (50.4%) 458 (51.1%) 269 (30.0%) 90 (41.1%)
Visits per subject 8.2 ± 3.7 9.1 ± 3.6 1.0 ± 0.0 1.1 ± 0.3
Age 73.0 ± 7.5 71.6 ± 7.2 71.9 ± 7.1 79.4 ± 7.0
Gender (% male) 59.3% 56.3% 58.0% 64.4%
MMSE 27.6 ± 1.8 28.0 ± 1.7 27.6 ± 2.2 28.1 ± 2.1
Converters (% total MCI) 117 (13.9%) 37 (8.1%) - 9 (10.0%)

Alzheimer’s Disease
Number (% total) 318 (19.1%) 69 (7.7%) 136 (15.2%) 29 (13.2%)
Visits per subject 4.9 ± 1.6 5.2 ± 2.6 1.0 ± 0.0 1.1 ± 0.3
Age 74.8 ± 7.7 75.1 ± 8.4 72.8 ± 7.1 82.2 ± 7.6
Gender (% male) 55.3% 68.1% 55.9% 51.7%
MMSE 23.3 ± 2.0 23.1 ± 2.0 20.5 ± 5.9 19.4 ± 7.2
Converters (% total AD) - - - 9 (31.0%)